TLDR:
- AMIX shares rise on PoC 1 data showing rapid pain relief in pancreatic patients.
- 93.75% of responding patients improved from severe to mild/moderate pain in 7 days.
- Two-thirds maintained mild or eliminated pain at 4–6 weeks post-procedure.
- No responding patients reported severe pain at 3 months; 50% retained relief.
- Company holds $7.5M cash; S-3 warrants could add $7.7M if exercised.
Autonomix (AMIX) shares traded at $0.4982 following new clinical subgroup data showing rapid and durable pain relief in pancreatic cancer patients.
Autonomix Medical, Inc. Common Stock, AMIX
The PoC 1 study data presented at ASCO GI 2026 revealed meaningful reductions in severe pain across Stage 2 through Stage 4 patients. The findings indicate potential palliative benefits, building on prior study results and ongoing transvascular RF denervation trials.
Clinical Subgroup Data Highlights Rapid Pain Relief
The post hoc analysis assessed outcomes in 16 patients responding to the treatment, including those with late-stage disease. Responding patients experienced significant pain reduction within 24 hours after the procedure. At seven days, 93.75% of patients improved from severe pain to mild or moderate levels, with some reporting near-elimination scores.
At 4–6 weeks, about two-thirds of the responding patients maintained mild or eliminated pain levels. By three months, no responding patients reported severe pain, and 50% eliminated pain. Some patients had limited long-term follow-up due to disease progression, while three patients had unknown cancer stage, slightly limiting clarity.
The analysis shows pain improvement occurs early and remains durable for most responders. The results reinforce the potential of targeted nerve-based interventions for severe pancreatic cancer pain. This data expands on previously reported ASCO GI 2026 findings and ongoing PoC program insights.
Potential Market and Financial Context
Autonomix holds $7.5 million in cash and equivalents at Q2 FY2026, with a going concern disclosure noted. An S-3 shelf registration allows the company to receive up to $7.7 million if common warrants are exercised. Shares traded below the 200-day moving average of $1.28 before the announcement, reflecting historical volatility near the 52-week low.
The registered resale of $13.5 million warrant shares could increase share count if exercised in cash. Recent company events, including European patent grants and conference presentations, have positively influenced stock price temporarily. Prior financing rounds caused sharp negative price reactions, highlighting sensitivity to capital-raising activities.
Autonomix continues platform development, IP expansion, and clinical research simultaneously. The company focuses on advancing precision nerve-targeted treatments with potential palliative impact. Capital structure, regulatory filings, and ongoing clinical updates remain central to investor evaluation.
Implications for Pancreatic Cancer Treatment
The study demonstrates consistent pain reduction across multiple disease stages, including late-stage patients with limited treatment options. Early onset and sustained benefit suggest transvascular RF denervation may provide meaningful relief where traditional therapies are insufficient. Future updates on three-month durability and expanded patient cohorts will further define clinical relevance.
These findings reinforce the potential of targeted, nerve-based approaches to address severe pancreatic cancer pain. The data could support regulatory discussions and provide a foundation for broader clinical adoption. Autonomix continues to integrate innovation, clinical evidence, and financial management to advance its therapeutic platform.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
